Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 17Completed 5Active not recruiting 5Not yet recruiting 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4Thoracic 2Gastrointestinal 1

Conditions

Stomach Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Fluorouracil 145Gemcitabine 141Oxaliplatin 135Capecitabine 133Leucovorin 107Irinotecan 99Bevacizumab 92Cetuximab 69Cisplatin 67pembrolizumab 61Radiotherapy 60Nivolumab 41130-nm albumin-bound paclitaxel 41Sorafenib 39Docetaxel 34Albumin-Bound Paclitaxel 31Radiosurgery 28Paclitaxel 27Surgical Procedures, Operative 25regorafenib 24Erlotinib Hydrochloride 23Panitumumab 22Cyclophosphamide 21Celecoxib 20Trastuzumab 19Radiation 18Neoadjuvant Therapy 18IFL protocol 18atezolizumab 17Carboplatin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × trastuzumab deruxtecan × Gastrointestinal × Clear all
NCT05091528 2022-08-18

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Silverback Therapeutics

Phase 1/2 Terminated
2 enrolled 9 charts
BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡